Inventiva S.A. – NASDAQ:IVA

Founder-led company

Inventiva S.A. stock price today

$4.48
+2.28
+103.64%
Financial Health
0
1
2
3
4
5
6
7
8
9

Inventiva S.A. stock price monthly change

-17.91%
month

Inventiva S.A. stock price quarterly change

-17.91%
quarter

Inventiva S.A. stock price yearly change

-51.43%
year

Inventiva S.A. key metrics

Market Cap
214.95M
Enterprise value
63.95M
P/E
-2.37
EV/Sales
32.62
EV/EBITDA
-1.61
Price/Sales
52.82
Price/Book
1.48
PEG ratio
0.08
EPS
-3.74
Revenue
29.65M
EBITDA
-166.52M
Income
-164.7M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-2090.13%
Oper. margin
-2014.38%
Gross margin
98.37%
EBIT margin
-2014.38%
EBITDA margin
-561.52%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Inventiva S.A. stock price history

Inventiva S.A. stock forecast

Inventiva S.A. financial statements

Inventiva S.A. (NASDAQ:IVA): Profit margin
Jun 2022 67K -29.46M -43979.1%
Dec 2022 12.11M -24.80M -204.82%
Jun 2023 1.90M -55.26M -2907.36%
Dec 2023 15.57M -55.15M -354.12%
Inventiva S.A. (NASDAQ:IVA): Analyst Estimates
2025 12.32M -86.60M -702.52%
2026 21.36M -98.55M -461.32%
2027 83.19M -48.52M -58.33%
2028 239.93M 30.89M 12.87%
  • Analysts Price target

  • Financials & Ratios estimates

Inventiva S.A. (NASDAQ:IVA): Debt to assets
Oct 2022 0 0
Dec 2022 116004000 70.52M 60.8%
Jun 2023 70819000 78.48M 110.83%
Dec 2023 69139000 101.59M 146.94%
Inventiva S.A. (NASDAQ:IVA): Cash Flow
Jun 2022 -26.22M -268K 13.95M
Dec 2022 -18.70M 9.13M 23.31M
Jun 2023 -45.23M -7.70M -2.15M
Dec 2023 -36.38M -29K 31.23M

Inventiva S.A. alternative data

Inventiva S.A. (NASDAQ:IVA): Employee count
Aug 2023 109
Sep 2023 109
Oct 2023 109
Nov 2023 117
Dec 2023 117
Jan 2024 117
Feb 2024 117
Mar 2024 117
Apr 2024 117
May 2024 120
Jun 2024 120
Jul 2024 120

Inventiva S.A. other data

0.09% -12.21%
of IVA is owned by hedge funds
37.82K -4.77M
shares is hold by hedge funds
Insider Compensation
Mr. Frederic Cren (1966) Co-Founder, Chief Executive Officer & Chairman
$437,360
Dr. Pierre Broqua (1962) Co-Founder, Chief Scientific Officer, Deputy Chief Executive Officer & Director
$331,780
Tuesday, 17 December 2024
globenewswire.com
Monday, 16 December 2024
globenewswire.com
Thursday, 12 December 2024
globenewswire.com
Thursday, 21 November 2024
globenewswire.com
Wednesday, 20 November 2024
globenewswire.com
Monday, 18 November 2024
businesswire.com
Friday, 15 November 2024
globenewswire.com
Wednesday, 30 October 2024
globenewswire.com
Monday, 21 October 2024
globenewswire.com
Monday, 14 October 2024
globenewswire.com
globenewswire.com
globenewswire.com
Tuesday, 1 October 2024
zacks.com
Wednesday, 25 September 2024
globenewswire.com
Wednesday, 31 July 2024
globenewswire.com
Thursday, 25 July 2024
globenewswire.com
Friday, 19 July 2024
globenewswire.com
Thursday, 18 July 2024
globenewswire.com
Monday, 8 July 2024
seekingalpha.com
Friday, 5 July 2024
globenewswire.com
Friday, 21 June 2024
globenewswire.com
Tuesday, 18 June 2024
zacks.com
Thursday, 30 May 2024
globenewswire.com
Wednesday, 22 May 2024
globenewswire.com
Tuesday, 21 May 2024
globenewswire.com
Thursday, 16 May 2024
globenewswire.com
Monday, 13 May 2024
globenewswire.com
Wednesday, 3 April 2024
globenewswire.com
Thursday, 28 March 2024
seekingalpha.com
globenewswire.com
  • What's the price of Inventiva S.A. stock today?

    One share of Inventiva S.A. stock can currently be purchased for approximately $4.48.

  • When is Inventiva S.A.'s next earnings date?

    Unfortunately, Inventiva S.A.'s (IVA) next earnings date is currently unknown.

  • Does Inventiva S.A. pay dividends?

    No, Inventiva S.A. does not pay dividends.

  • How much money does Inventiva S.A. make?

    Inventiva S.A. has a market capitalization of 214.95M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 43.5% to 17.48M US dollars.

  • What is Inventiva S.A.'s stock symbol?

    Inventiva S.A. is traded on the NASDAQ under the ticker symbol "IVA".

  • What is Inventiva S.A.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Inventiva S.A.?

    Shares of Inventiva S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Inventiva S.A.'s key executives?

    Inventiva S.A.'s management team includes the following people:

    • Mr. Frederic Cren Co-Founder, Chief Executive Officer & Chairman(age: 59, pay: $437,360)
    • Dr. Pierre Broqua Co-Founder, Chief Scientific Officer, Deputy Chief Executive Officer & Director(age: 63, pay: $331,780)
  • Is Inventiva S.A. founder-led company?

    Yes, Inventiva S.A. is a company led by its founders Mr. Frederic Cren and Dr. Pierre Broqua.

  • How many employees does Inventiva S.A. have?

    As Jul 2024, Inventiva S.A. employs 120 workers, which is 3% more then previous quarter.

  • When Inventiva S.A. went public?

    Inventiva S.A. is publicly traded company for more then 5 years since IPO on 10 Jul 2020.

  • What is Inventiva S.A.'s official website?

    The official website for Inventiva S.A. is inventivapharma.com.

  • How can i contact Inventiva S.A.?

    Inventiva S.A. can be reached via phone at +33 3 80 44 75 00.

Inventiva S.A. company profile:

Inventiva S.A.

inventivapharma.com
Exchange:

NASDAQ

Full time employees:

123

Industry:

Biotechnology

Sector:

Healthcare

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

50 rue de Dijon
Daix, 21121

CIK: 0001756594
ISIN: US46124U1079
CUSIP: 46124U107